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Pneumonitis is a well-described, potentially life-threatening adverse effect of immune checkpoint inhibitors (ICI) and thoracic
radiotherapy. It can require additional investigations, treatment, and interruption of cancer therapy. It is important for clinicians
to have an awareness of its incidence and severity, however real-world data are lacking and do not always correlate with findings
from clinical trials. Similarly, there is a dearth of information on cost impact of symptomatic pneumonitis. Informatics approaches
are increasingly being applied to healthcare data for their ability to identify specific patient cohorts efficiently, at scale.
We developed a Structured Query Language (SQL)-based informatics algorithm which we applied to CT report text to identify cases
of ICI and radiotherapy pneumonitis between 1/1/2015-31/12/2020. Further data on severity, investigations, medical management
were also acquired from the electronic health record.
We identified 248 cases of pneumonitis attributable to ICI and/or radiotherapy, of which 139 were symptomatic with CTCAE
severity grade 2 or more. The grade 2+ ICI pneumonitis incidence in our cohort is 5.43%, greater than the all-grade 1.3-2.7%
incidence reported in the literature. Time to onset of ICI pneumonitis was also longer in our cohort (mean 4.5 months, range 4
days-21 months), compared to the median 2.7 months (range 9 days-19.2 months) described in the literature. The estimated
average healthcare cost of symptomatic pneumonitis is £3932.33 per patient.
In this study we use an informatics approach to present new real-world data on the incidence, severity, management, and
resource burden of ICI and radiotherapy pneumonitis. To our knowledge, this is the first study to look at real-world incidence and
healthcare resource utilisation at the per-patient level in a UK cancer hospital. Improved management of pneumonitis may
facilitate prompt continuation of cancer therapy, and improved outcomes for this not insubstantial cohort of patients.
  
 Contribution to the field
Pneumonitis is a well-described, potentially life-threatening adverse effect of immune checkpoint inhibitors (ICI) and thoracic
radiotherapy. It can require additional investigations, treatment, and interruption of cancer treatment. It is important for
clinicians to have an awareness of its incidence and severity, however real-world data are lacking and do not always correlate
with findings from clinical trials. Similarly, there is a dearth of information on cost impact of symptomatic pneumonitis.
Informatics approaches are increasingly being applied to healthcare data for their ability to identify specific patient cohorts
efficiently, at scale. In this study, we draw upon a Structured Query Language (SQL)-based informatics approach to present new
real-world data on the incidence, severity, management, and resource burden of ICI and radiotherapy pneumonitis. To our
knowledge, this is the first study to look at real-world incidence and healthcare resource utilisation at the per-patient level in a
UK cancer hospital. The latter is an important contribution, providing useful health economics data to inform future studies
assessing cost-effectiveness of pneumonitis-related healthcare pathways. Additionally, we contribute evidence to the literature on
the utility of informatics tools to extract real-world data from the electronic health record with reduced need for clinician time
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Abstract 22 
Pneumonitis is a well-described, potentially life-threatening adverse effect of immune checkpoint 23 
inhibitors (ICI) and thoracic radiotherapy. It can require additional investigations, treatment, and 24 
interruption of cancer therapy. It is important for clinicians to have an awareness of its incidence and 25 
severity, however real-world data are lacking and do not always correlate with findings from clinical 26 
trials. Similarly, there is a dearth of information on cost impact of symptomatic pneumonitis. 27 
Informatics approaches are increasingly being applied to healthcare data for their ability to identify 28 
specific patient cohorts efficiently, at scale.  29 
We developed a Structured Query Language (SQL)-based informatics algorithm which we applied to 30 
CT report text to identify cases of ICI and radiotherapy pneumonitis between 1/1/2015-31/12/2020. 31 
Further data on severity, investigations, medical management were also acquired from the electronic 32 
health record.  33 
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We identified 248 cases of pneumonitis attributable to ICI and/or radiotherapy, of which 139 were 34 
symptomatic with CTCAE severity grade 2 or more. The grade ≥2+ ICI pneumonitis incidence in our 35 
cohort is 5.43%, greater than the all-grade 1.3-2.7% incidence reported in the literature. Time to 36 
onset of ICI pneumonitis was also longer in our cohort (mean 4.5 months, range 4 days-21 months), 37 
compared to the median 2.7 months (range 9 days-19.2 months) described in the literature. The 38 
estimated average healthcare cost of symptomatic pneumonitis is £3932.33 per patient.  39 
In this study we use an informatics approach to present new real-world data on the incidence, 40 
severity, management, and resource burden of ICI and radiotherapy pneumonitis. To our knowledge, 41 
this is the first study to look at real-world incidence and healthcare resource utilisation at the per-42 
patient level in a UK cancer hospital. Improved management of pneumonitis may facilitate prompt 43 
continuation of cancer therapy, and improved outcomes for this not insubstantial cohort of patients. 44 
 45 
1 Introduction 46 
Pneumonitis is a well-described, potentially life-threatening and disabling adverse effect of several 47 
cancer therapies including immune checkpoint inhibitor (ICI) drugs and thoracic radiotherapy. The 48 
advent of ICI drugs, such as those targeting the Programmed Cell Death 1 receptor or its ligand 49 
(PD1/PD-L1), have transformed cancer treatment over the last decade. The numbers of patients 50 
receiving such drugs either alone or in combination therapy for various cancers continues to increase 51 
and an abundance of clinical trials elaborate upon further applications(1,2). Radiotherapy continues 52 
to be a major treatment modality for lung cancer and with an aging and increasingly comorbid 53 
population, the number of patients treated curatively with radiotherapy rather than surgery is likely to 54 
increase. As pneumonitis is observed in up to 5% of patients treated with ICI(3–5) and 40% 55 
following radiotherapy(6), it is likely to present a growing problem in cancer care. As pneumonitis 56 
can result in significant morbidity, preclusion of further treatment and even death(7), it is important 57 
for clinicians to have an awareness of its incidence and severity.  58 
There is a lack of real-world incidence data in the literature, and that which exists does not always 59 
correlate with findings from clinical trials(8). Similarly, there is a dearth of information on health 60 
resource utilisation by patients with pneumonitis, which is an important element of economic 61 
evaluation studies seeking to explore whether new approaches to treatment are cost-effective. 62 
Informatics approaches are increasingly being applied to healthcare data for their ability to identify 63 
specific patient cohorts at scale, more efficiently than traditional manual approaches. Here we use 64 
informatics tools to assist identification of cases of ICI and radiotherapy-pneumonitis and describe 65 
data on clinical management and impact of such cases in our specialist cancer centre from 2015-2020 66 
inclusive. 67 
2 Materials and Methods 68 
Using our integrated data warehouse and electronic health record (EHR) systems, we developed a 69 
Structured Query Language (SQL)-based informatics algorithm which we applied to CT Thorax 70 
report text to identify scans performed between 01/01/2015 and 31/12/2020 that contained key terms 71 
determined by radiology and respiratory expertise: “pneumonitis”, “pulmonary toxicity”, “lung 72 
toxicity”, “lung injury”, “interstitial lung disease” and “pneumonia”. This generated a list of 3,632 73 
CT reports. The report text, scan date and patient identifiers were extracted along with additional 74 
demographic and treatment details.  75 
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Such terms were typically located within the “request details” section of the report, where the 76 
requesting clinician had queried presence of “pneumonitis”, separately from the radiologist’s 77 
findings. In order to identify CT reports where the body of the report described findings relating to 78 
possible pneumonitis, further rules were applied to filter reports containing the terms “ground glass”, 79 
“treatment”, “drug”, “diffuse”, “infiltrates”, “radiotherapy”, “radiation” again guided by respiratory 80 
and radiology expertise. This filtered the number of reports down to 2,416.  81 
Filters were also applied to structured treatment fields to identify only patients who had received any 82 
of the ICI drugs prescribed at our centre (Atezolizumab, Avelumab, Durvalumab, Ipilimumab, 83 
Nivolumab, Pembrolizumab) and/or to identify all patients that had received radiotherapy to the 84 
thorax/upper abdomen/neck/vertebrae/breast/chest wall prior to the date of the flagged CT report. A 85 
manual validation step was undertaken to eliminate any reports that did not suggest a possible 86 
pneumonitis. Reports from additional scans performed within 6 months of the identified scan for 87 
each patient were also eliminated, to limit the dataset to the earliest CT with reported pneumonitis.  88 
The EHR of all patients with pneumonitis possibly attributable to ICI and/or RT was manually 89 
reviewed to identify the earliest date where potential pneumonitis symptoms (e.g. cough, dyspnoea) 90 
or clinical reference to pneumonitis began, and to ascertain severity of pneumonitis, which was 91 
inferred according to CTCAE v5.0 criteria (Supplementary Table 1). A case of pneumonitis was 92 
defined as a radiological report consistent with pneumonitis or treating clinician or multidisciplinary 93 
meeting consensus of pneumonitis based on the clinical picture at the time of presentation. 94 
Pneumonitis was attributed to ICI if one of the above six drugs was administered within the 95 
preceeding three months, and considered radiotherapy-related if the patient was treated with radiation 96 
in the preceeding twelve months. Fifty cases from the final cohort (20%) were randomly selected for 97 
independent review and scoring of CTCAE severity by a second clinician. The Krippendorff’s alpha 98 
measure of inter-observer correlation(9) was used to check concordance between both clinicians’ 99 
interpretation of severity, calculated using the Natural Language ToolKit (NLTK) package in Python 100 
v 3.9.  101 
Where symptoms were CTCAE grade 2 or more or treatment was withdrawn, additional data 102 
including investigations and medical management with steroids and/or antibiotics were collected 103 
manually from the EHR. Where a patient had more than one distinct episode of pneumonitis, this was 104 
recorded as a separate case. Further data were collected from the pharmacy database on the total 105 
number of patients treated with the above-mentioned ICI drugs (as mono- or combination-therapy) 106 
between 2015-2020 and for all patients deemed to have ICI or radiotherapy-related pneumonitis, 107 
clinical activity data was extracted algorithmically from the EHR including total number of 108 
consultant follow-up clinic attendances, CT thorax scan appointments and MDT discussions for the 109 
16-weeks after the date of pneumonitis diagnosis. 110 
 111 
3 Results 112 
3.1 The Cohort 113 
We identified 450 CT reports indicating a pneumonitis in patients who had previously received ICI 114 
and/or radiotherapy, and thus which was possibly attributable to ICI/RT amongst other cause Figure 115 
1).  In 248 cases (from 242 patients), the pneumonitis was attributed by the treating team as partially 116 
or completely due to ICI and/or radiotherapy-pneumonitis. In some cases, infection and other co-117 
morbidities (e.g. pulmonary embolus or COPD) may have also contributed to the presentation as per 118 
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the clinical opinion of the treating team at the time; for example due to CT pulmonary angiogram 119 
results demonstrating the presence of both pulmonary emboli and features in keeping with 120 
pneumonitis, or raised inflammatory markers and pyrexia at presentation which responded to 121 
antibiotic therapy. One hundred and nine cases were asymptomatic (grade 1) and 139 were 122 
symptomatic with severity grade 2 or more. Results of symptomatic cases are presented below. 123 
Table 1 shows the demographic and aetiology breakdown of symptomatic cases. Of the 139 124 
symptomatic cases, 61% of patients were male, the majority were performance status 0-1 and 20.14% 125 
were never-smokers. ICI accounted for 61.15% of cases with 7.19% of cases attributed to a 126 
combination of both ICI and radiotherapy.  127 
Three quarters of cases were of grade 2 severity, 10.79% were grade 3 severity, 4 patients (2.88%) 128 
required intubation (grade 4) and 13 patients (9.35%) died (grade 5) (Figure 2). Of those that died, 129 
average time from first diagnosis of pneumonitis to death was 64 days (range 6-378). The number of 130 
cases increased year-on-year until 2020 after which there was a marked reduction (Figure 3). For the 131 
50 cases where a second clinician independently reviewed and scored CTCAE severity, the 132 
Krippendorff’s alpha measure of inter-observer correlation demonstrated high concordance at 0.97.  133 
One hundred and thirty-four symptomatic cases (96.4%) were treated with intravenous or oral 134 
steroids (Table 2). Two patients declined, 1 was treated with a steroid inhaler and in one grade 2 case, 135 
steroids were withheld due to concerns of possible COVID-19 and on-going tumour response to 136 
immunotherapy. A third of cases treated with oral steroids were given prophylactic co-trimoxazole at 137 
the time of steroid initiation, and this was mostly in cases where pneumonitis was described in the 138 
EHR to be ICI-related. Seventy-nine cases (57%) were treated with empirical antibiotics at initial 139 
presentation. Six cases (all ICI-pneumonitis) went on to receive another immunosuppressive therapy 140 
(Infliximab or Mycophenolate Mofetil).  141 
Fifty-eight cases (42%) were referred for specialist respiratory management. The average time from 142 
first presentation with pneumonitis to being seen by the respiratory service was 34 days (range 0-143 
215) with 40% and 55% of cases seen within 2 and 3 weeks of pneumonitis diagnosis respectively. 144 
Thirty-three cases (24%) went on to have a bronchoalveolar lavage (BAL). The average time from 145 
first presentation with pneumonitis to BAL was 35 days (range 1-149), with 58% of cases having 146 
BAL within 3 weeks. For those with grade 2 severity (n=20), average time to BAL was 41 days 147 
(range 1-149), and for those with grade 3-5 severity, was 24 days (range 1-91). Twelve cases (8.7%) 148 
had documented evidence of pulmonary function tests (PFTs) following diagnosis with pneumonitis.  149 
Fifty-four cases were admitted to hospital with 10 requiring admission to critical care (CCU). The 150 
average length of hospital and CCU admission was 10.5 days (range 1-43) and 6.5 days (range 1-20) 151 
respectively. 152 
3.2 ICI related cases 153 
Of the 85 cases attributed to ICI, 32 (37.6%) had received pembrolizumab, 20 (23.5%) had received 154 
nivolumab and 11 (12.9%) combination therapy with ipilimumab and nivolumab (Supplementary 155 
Table 2). Thirteen (15.3%) were considered to have superadded infection. Three cases (3.5%) were 156 
due to a flare of underlying fibrosis or severe sarcoid-like reaction from ICI.  157 
The mean time from starting ICI therapy to first presentation with pneumonitis was 4.5 months 158 
(range 4 days – 21 months). Forty-eight percent of cases presented within 3 months.  159 
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In 4 cases, patients had completed ICI therapy at the time of presenting with pneumonitis. Of the 160 
remaining 81 cases, 28 (34.6%) were re-challenged with ICI therapy. The mean lost treatment time 161 
between ICI being held and reintroduced was 73 days (range 11-275), however in some cases this 162 
was due to other toxicities e.g. ICI-mediated colitis. Of the 28 cases that were re-challenged, 6 163 
(21.4%) had recurrence of pneumonitis and had to stop treatment. In 6 cases (21.4%), patients had 164 
disease progression within 2 cycles after resuming ICI and then stopped treatment. For these 6 cases, 165 
the average treatment interruption was 74 days (range 29-150). 166 
A total of 1565 patients were treated with ICI therapy in our centre between 2015-2020. Of these, we 167 
identified 85 (5.43%) that developed symptomatic ICI-related pneumonitis (N.B. the 10 patients with 168 
pneumonitis considered to be due to both RT and ICI therapy are not described here). Table 3 169 
describes the proportion of pneumonitis cases by tumour-group, the highest of which were head and 170 
neck and lung cancers. Figure 2 describes the number of ICI-pneumonitis cases by severity. Of the 171 
total number of patients treated with ICI therapy, 62 (3.96%) were Grade 2, 11 (0.7%) were Grade 3, 172 
4 (0.26%) were Grade 4 and 8 (0.51%) were Grade 5 respectively.  173 
 174 
3.3 RT related cases 175 
Forty-four cases were attributed to RT, of which 8 (18%) had received palliative dose-fractionation 176 
schedules (ranging from 20 Gy in 5 fractions to 39 Gy in 13 fractions). The mean time from first 177 
fraction of radiotherapy to first presentation with pneumonitis was 3.6 months (range 8 days-8 178 
months). Nine cases (20.5%) were considered to have superadded infection. Of the total number 179 
treated with RT, 35 (79.5%) were Grade 2, 4 (9.1%) were Grade 3 and 5 (11.4%) were Grade 5, 180 
including 2 patients (4.5%) that had underlying fibrosis thought to be exacerbated by RT and both 181 
patients died. The number of RT related cases were stable at approximately 10 per year between 182 
2015-2020 (Figure 3). 183 
 184 
3.4 Mixed RT and ICI related cases 185 
Ten cases were in patients with a diagnosis of non-small cell lung cancer (NSCLC) who had received 186 
both RT and ICI prior to presenting with pneumonitis. All 10 cases were of grade 2 severity. Of 187 
these, 6 patients (60%) received Durvalumab. Five had prior treatment with concurrent 188 
chemoradiotherapy (60-66Gy in 30-33 fractions) and one received Durvalumab after sequential 189 
chemoradiotherapy 55Gy in 20 fractions). The remaining patients were treated with Pembrolizumab 190 
(3 cases) or Atezolizumab (1 case) and palliative dose fractionation schedules (ranging from 20Gy in 191 
5 fractions to 36Gy in 12 fractions). Three cases (30%) were considered to have superadded 192 
infection. 193 
 194 
3.5 Healthcare Resource Utilisation  195 
The number of consultant follow-up clinic, CT thorax appointments and MDT discussions in the 16 196 
weeks following pneumonitis diagnosis was compared between patients with grade 1 and grade 2-4 197 
severity (Figure 4). The number of CT thorax scans and MDT discussions were broadly equal across 198 
the groups however patients with grade 2-4 severity had approximately 50% more consultant follow-199 
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up clinic appointments (unpaired t-test: P value <0.0001, difference in mean = 2.21, CI 1.34-3.07). 200 
Of the patients with grade 2-5 pneumonitis, 54 (39%) were admitted to hospital and 10 (7%) to CCU. 201 
The average duration of hospital admission was 10.5 days (range 1-43) per patient and CCU 202 
admission was 6.5 days (range 1-20) per patient.  203 
In Table 4 we present the average use of resources associated with managing a symptomatic 204 
pneumonitis case. We recognise that resource utilisation will vary depending on severity and not 205 
every resource will be used for every case. Estimates for units used are based on data from this study 206 
(indicated with *) and expert opinion (indicated with ^) on additional resources that gold-standard 207 
care is expected to include (PFTs and follow-up consultation for all cases requiring referral for 208 
specialist respiratory opinion). Units used have been weighted based on study data on the expected 209 
average use of resources by patients. For example, based on our data, only 4.3% of cases required 210 
other immunosuppressive therapy, only 41.7% a respiratory referral, and 23.7% bronchoscopy. Costs 211 
per unit were derived from the National Schedule of NHS costs 2019/2020 (NHS reference costs)(10) 212 
and British National Formulary (BNF)(11) and allow estimates on the average costs of healthcare per 213 
symptomatic pneumonitis case to be made (£3,932.33). 214 
This is a conservative estimate as we have not included costs for empirical antibiotics, steroids, co-215 
trimoxazole, pathology and microbiology services and have accounted only for CT thorax imaging, 216 
whereas in practice patients are likely to have had CT thorax, abdomen, and pelvis imaging. 217 
Furthermore, we have assumed patients that were referred for specialist respiratory input had only 218 
one initial and one follow-up appointment whereas in practice the number of follow-up appointments 219 
may have been higher. 220 
To put this into context, applying the average cost per patient to the 139 symptomatic cases in our 221 
study who were treated at our centre between 2015-2020 leads to a total cost of £546,594.52. This is 222 
a cost of £91,099.09 per year. 223 
 224 
4 Discussion 225 
In this study we present new real-world data on the incidence, severity, management, and resource 226 
burden of cancer therapy pneumonitis. To our knowledge, this is the first study to look at real-world 227 
incidence and healthcare resource utilisation at the per-patient level in a UK cancer hospital. The 228 
latter is an important contribution, providing useful health economics data to inform future studies 229 
assessing cost-effectiveness of pneumonitis-related healthcare pathways. Additionally, we contribute 230 
evidence to the literature on the utility of informatics tools to extract real-world data from the EHR 231 
with reduced need for clinician time to manually collect such data.  232 
The grade 2 or higher ICI-pneumonitis incidence in our cohort is 5.43%, which is greater than the all-233 
grade 1.3-2.7% incidence reported in the literature(4,5) and higher than the all-grade pneumonitis 234 
from a large real-world series by Naidoo et al(3). For example, a meta-analysis of PD-1 inhibitor 235 
pneumonitis by Nishino et al demonstrated an all-grade incidence of 2.7%(5). Whilst our study also 236 
included PDL-1 and CTLA-4 related pneumonitis, making direct comparison difficult, this value is 237 
much lower than seen in our cohort. Similarly, grade 3-5 incidence in our cohort was 1.49%, higher 238 
than the 0.8% Grade 3-5 PD-1 pneumonitis rate described by Nishino et al(5). Time to onset of ICI-239 
pneumonitis was also longer in our cohort (mean 4.5 months, range 4 days-21 months), compared to 240 
the median 2.7 months (range 9 days-19.2 months) described by Naidoo et al(3). In ninety-one 241 
patients receiving adjuvant Durvalumab following RT for NSCLC at our centre over the study 242 
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period, 6 (6.59%) developed pneumonitis, all of which were grade 2 severity. Our data demonstrates 243 
lower rates of grade 3-4 pneumonitis than the PACIFIC study, which reported all-grade and grade 3-244 
4 pneumonitis rates of 12.6% and 1.9% respectively.  245 
The incidence of pneumonitis in patients treated with combination ipilimumab and nivolumab was 246 
3.75%, lower compared to the incidence from single agent ICI. This contrasts findings in the 247 
literature which describe ICI-related pneumonitis most commonly occurring in patients receiving 248 
combination treatment(3,8). A higher incidence of ICI-pneumonitis is reported in patients with non-249 
small cell lung cancer and with squamous cancers(5,8). This is reflected in our cohort which 250 
demonstrated highest incidence in head and neck (11.48%) and lung (9.01%) tumour groups.  251 
Twenty-eight patients who developed ICI-pneumonitis at our centre had ICI re-introduced on 252 
resolution of symptoms. Six (21.4%) had disease progression within 2 cycles of restarting treatment. 253 
The average interruption in treatment was 74 days (range 29-150) and it is possible that this 254 
interruption may have led to loss of immunomodulation and control of cancer. 255 
Almost 20% of RT pneumonitis cases had received palliative dose-fractionation schedules. Whilst 256 
there may be confounding factors including larger irradiated volume and possibly frailer patients with 257 
heart-failure or disease progression contributing to the presentation, this may be an important factor 258 
when considering quality of life in deciding which patients would benefit from palliative treatment.  259 
Mean time to onset of RT pneumonitis in our cohort fit with that described in the literature(6).    260 
Of note, the number of cases of ICI-pneumonitis increased year on year from 2015-19 but then 261 
reduced in 2020. This is inconsistent with the number of patients treated with ICI overall at our 262 
centre which continued to increase in 2020 (Supplementary Table 3). The explanation for this is 263 
likely multifactorial, however one possibility may be the impact of the COVID-19 pandemic, due to 264 
increased local hospital care or misdiagnosis of ICI-pneumonitis as COVID-19 due to overlapping 265 
clinical and radiological features(12–14), particularly if patients presented to departments less 266 
familiar with the diagnosis and management of ICI-toxicity. It is possible that growing understanding 267 
of ICI-pneumonitis results in earlier identification and optimal management. In particular, there is a 268 
need to identify patients at risk of developing grade ≥3+ pneumonitis as early as possible and this is 269 
an area where artificial intelligence and machine learning predictive models may provide significant 270 
clinical utility.   271 
Such considerations support the need for wider education on cancer therapy toxicity including 272 
differential diagnoses and the potential role of acute oncology, respiratory and microbiology services 273 
in recognising this. Continued surveillance and analysis of pneumonitis incidence will be important 274 
and may be benefited by a national pneumonitis registry. Here we have provided an indicative list of 275 
resource use for symptomatic pneumonitis based on a combination of study data and expert opinion, 276 
and an indicative, conservative estimate of healthcare cost per patient. Whilst we do not have data on 277 
the UK-wide incidence for ICI or radiotherapy-pneumonitis to provide estimates at population-level, 278 
the economic impact at our centre is estimated at over £90,000 per year. Earlier detection and 279 
improved management of pneumonitis could potentially reduce such costs. Future research on the 280 
health economic aspects of ICI or radiotherapy-pneumonitis will allow us to estimate more precisely 281 
the economic burden on the NHS.  282 
Our study has several limitations. Due to its retrospective nature, the data presented relies on EHR 283 
documentation which may contain inaccuracies, especially when referring to investigations 284 
performed outside our centre such as BAL and PFTs. An example was concurrent administration of 285 
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prophylactic co-trimoxazole with steroids which appeared variable. It is difficult to ascertain from 286 
retrospective EHR data the reasons for this. One explanation is that steroids were started on the 287 
assumption that symptoms would improve and when they didn’t, the course was extended and 288 
prophylactic co-trimoxazole was introduced. Improved education on recording key clinical decisions 289 
in medical notes is often encouraged as a gold-standard of documentation. Considering informatics 290 
requirements with respect to such principles highlights a need for more structured data fields that in-291 
turn could integrate with drug toxicity analytics and decision support systems – e.g. the recording of 292 
a steroid prescription in the EHR then presents the clinician with a data field asking if prophylactic 293 
co-trimoxazole, proton-pump inhibitor or bisphosphonate is indicated, thus providing additional data 294 
at the same time as standardising care.  295 
A further limitation of informatics approaches is that the identification of cases is dependent on 296 
defining comprehensive search terms. Missed cases, or indeed those investigated with chest x-ray 297 
rather than CT would lead to underestimates of the incidence of pneumonitis in this cohort or favour 298 
identification of milder cases that are defined with radiological reports but not actioned by clinical 299 
teams as significant. Informatics approaches do however tend to be more comprehensive than manual 300 
searches for cases given their broad vision of the entire EHR dataset and are therefore a valuable 301 
route to define descriptive statistics of the broader cohort identified, which may improve upon more 302 
traditional methods of audit and research and can be scaled up to larger data sets, with less person-303 
hour requirements. 304 
This is a single-centre study and therefore may not reflect variation in practice across centres, but our 305 
experience is that such tools can be readily applied in other centres and are thus well placed to drive 306 
acquisition of much larger datasets, in collaboration with others, where this can facilitate greater 307 
understanding and allow comparison between centres or creation of a lung toxicity registry. 308 
Overall, the use of ICI has increased over the last 6 years and with that as has the incidence of ICI-309 
related pneumonitis. Our data suggests the incidence of ICI-pneumonitis is higher, and time to onset 310 
is longer compared to the literature. The number of patients receiving ICI therapy and subsequently 311 
the number presenting with possible ICI-pneumonitis is likely to continue to increase, placing 312 
demand on acute oncology and specialist respiratory services, and potentially hospital and CCU 313 
admissions. It is imperative that funding and resource provision is made available to support 314 
increasing demand on such pathways and to ensure adequate provision of acute oncology, respiratory 315 
and microbiology services - for example, rapid access to BAL to aid diagnosis, and PFTs to define 316 
severity. Improved management of pneumonitis may facilitate prompt continuation of cancer therapy, 317 
and improved outcomes for this not insubstantial proportion of our ICI or thoracic radiotherapy 318 
treated patients.  319 
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available, in keeping with the organisation’s Data Protection Policy. 360 
 361 
2 Figure Captions 362 
Figure 1: Flow of data to identify cases for inclusion. RT = radiotherapy. 363 
Figure 2: Symptomatic pneumonitis severity by cause. 364 
Figure 3: Number of symptomatic cases per year by cause. 365 
Figure 4: The mean number of cases requiring CT thorax scan, MDT discussion and consultant 366 
follow-up clinic appointment in the 16 weeks following pneumonitis diagnosis, by severity. 367 
3 Tables 368 
Table 1: Symptomatic (grade ≥2+) pneumonitis demographics and aetiology. 369 
Demographics and Causes Number 














































Table 2: Medical treatment, investigation, and management for symptomatic pneumonitis.  372 
Medical treatment  All Cases 
[n=139] 
ICI Cases  
[n=85] 
RT Cases  
[n=44] 
RT and ICI 
Cases [n=10] 
Empirical antibiotics 79 (56.8%) 49 (57.6%) 25 (56.8%)  5 (50%) 
Steroids (oral or intravenous) 134 (96.4%) 84 (98.8%) 40 (90.9%) 10 (100%) 
Prophylactic co-trimoxazole at initiation of oral steroids 41 (29.5%) 37 (43.5%) 1 (2.3%) 3 (30%) 
Other immunosuppressive agent 6 (4.3%) 6 (7.1%) 0 0 
Investigation and management     
Referral to Respiratory Specialist 58 (41.7%) 40 (47%) 15 (34%) 3 (30%) 
Average time [and range] from pneumonitis diagnosis to 
respiratory review (days) 
34 [0-215] 30 [0-135] 35 [2-128] 75 [2-215] 
Broncho-alveolar lavage 33 (23.7%) 28 (32.9%) 5 (11.4%) 0 
Average time [and range] from pneumonitis diagnosis to BAL 
(days) 
35 [1-149] 32 [1-149] 52 [6-128] NA 
Pulmonary function test (PFT) following diagnosis of 
pneumonitis 
12 (8.6%) 9 (10.6%) 3 (6.8%) 0 
Admission to hospital 54 (38.8%) 39 (45.9%) 13 (29.5%) 2 (20%) 
Average duration [and range] of hospital admission (days) 10.5 [1-43] 10 [1-43] 15 [1-39] 2 [1-2] 
Admission to CCU/ITU 10 (7.2%) 7 (8.2%) 3 (6.8%) 0 
Average duration [and range] of CCU/ITU admission (days) 6.5 [1-20] 7 [1-20] 7 [3-11] NA 
 373 
Table 3: The number of patients receiving ICI therapy and developing symptomatic ICI-related 374 
pneumonitis between 2015-2020. 375 







pneumonitis cases by 
tumour group (%) 
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Breast 35 - - 
GI 144 10 6.9 
Gynae 47 - - 
H&N 61 7 11.5 
Lung 433 39 9.0 
Lymphoma 25 - - 
Sarcoma 29 2 6.9 
Skin 522 18 3.4 
Urology 269 9 3.3 
 376 
Table 4: The estimated average per-patient cost of symptomatic pneumonitis based on NHS reference 377 
and BNF unit costs. FU – follow up, CL- consultant led, OPROC-outpatient procedures, IMAG – 378 
Diagnostic Imaging, CMDT-Cancer multidisciplinary team meetings, CC-Critical Care, NES- Non-379 
elective short stay. Resource utilisation units have been based on data extracted from healthcare 380 
records (*) or expert opinion (^) and have been weighted based on study data on the expected 381 
average use of resources. Infliximab is used here as an example of “other immunosuppressive agent”. 382 
The cost per unit is based on a course of 5mg/kg twice daily for 5 days. For a 70kg patient this is 383 
3500mg. The BNF cost is £377 for 100mg. 384 





Currency or service code Total 
Estimated 
Cost (£) 
Initial respiratory appointment (CL)* 0.417 198.52 WF01B 82.78 
FU respiratory appointment (CL) ^ 0.417 209.12 WF02A 87.20 
Bronchoscopy* 0.237 703.86 DZ69A (OPROC) 166.81 
PFT ^ 0.417 156.75 DZ52Z (OPROC) 65.36 
CT Thorax scan* 1 68.92 RD21A (IMAG, outpatient) 68.92 
MDT discussion* 1 127.45 Average of CMDT-B, -C, -LG, -OTH, -SPU, -
SPG 
127.45 
FU Oncology appointment (CL) * 2 200.38 WF01A 400.76 
Hospital admission (nights) * 10.5 x 0.07 473.97 DZ19M (NES) 1,940.91 
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CCU admission (nights)* 6.5 x0.39 933.51 CCU03, XC06Z (CC) 424.75 
Other immunosuppressive agent* 0.043 13,195 BNF 567.39 
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